Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04938141 · ClinicalTrials.gov registry record
MEOI and HRQoL in CLL Patients Treated With BTKis
A clinical trial of Chronic Lymphocytic Leukemia, sponsored by AstraZeneca.
- Completed
- Registry status
- 23
- Enrollment target
- 16
- Study locations
NCT04938141 is a study of Chronic Lymphocytic Leukemia that has completed, run by AstraZeneca. The registered enrollment target is 23 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The trial reports 16 study locations across 9 states.
The verdict
NCT04938141, a study of Chronic Lymphocytic Leukemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
Conditions Studied
Study Locations (16)
Florida
- Research Site - Boca Raton
- Research Site - Fort Lauderdale
- Research Site - St. Petersburg
- Research Site - Tallahassee
- Research Site - Tamarac
- Research Site - Tampa
California
- Research Site - Fountain Valley
- Research Site - Redlands
Pennsylvania
- Research Site - Philadelphia
- Research Site - York
Georgia
- Research Site - Savannah
Hawaii
- Research Site - Honolulu
Mississippi
- Research Site - Jackson
New Jersey
- Research Site - Berkeley Heights
New York
- Research Site - Amherst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2024-09-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04938141
The ClinicalTrials.gov registry entry for NCT04938141 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT04938141 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04938141 about?
NCT04938141 is a clinical study titled "MEOI and HRQoL in CLL Patients Treated With BTKis". This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
What is the current status of trial NCT04938141?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2021-10-07. Estimated completion is 2024-09-26.
What conditions does trial NCT04938141 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
Who is sponsoring clinical trial NCT04938141?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04938141 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Hawaii, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.